A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Home
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Conditions: Advanced Unresectable Gastric Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Advanced Gastroesophageal Adenocarcinoma

Interventions: Drug: Tislelizumab; Drug: Capecitabine; Drug: 5-fluorouracil (5-FU); Drug: Oxaliplatin; Drug: Leucovorin

Sponsors: BeOne Medicines

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 12, 2026ClinicalTrials.govComments OffGastroenterologyClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine

Comments